PT-141 (Bremelanotide)

Discovery & Origins: From Melanotan II to PT-141

PT-141, also known as Bremelanotide, emerged from a lineage of synthetic melanocortin peptide research that began with the isolation of alpha-melanocyte-stimulating hormone (α-MSH) and subsequent efforts to create more stable, potent analogues. The direct precursor to PT-141 was Melanotan II (MT-II), a cyclic lactam analogue of α-MSH developed by researchers at the University of Arizona in the 1990s.

During in vitro and preclinical studies of Melanotan II, researchers investigating the peptide's melanocortin receptor binding profile observed unexpected downstream effects mediated through central MC3R and MC4R activation. This observation — distinct from the pigmentation-related effects mediated through MC1R — prompted a new line of inquiry focused specifically on melanocortin receptor subtypes expressed in the hypothalamus and limbic system.^[1]

PT-141 was synthesized as a metabolite/modification of Melanotan II through hydrolysis of the cyclic lactam bridge, yielding a linear heptapeptide: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. This structural change altered receptor binding kinetics while preserving central melanocortin agonist activity, creating a compound with distinct pharmacodynamic properties compared to its parent molecule.^[2]

Molecular Structure & Classification

PT-141 belongs to the melanocortin peptide family, a class of endogenous and synthetic peptides that bind to the five known melanocortin receptor subtypes (MC1R–MC5R). The compound is classified as a cyclic heptapeptide with the following key structural features:

• Molecular Formula: C₅₀H₆₈N₁₄O₁₀
• Molecular Weight: ~1025.2 Da
• Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
• D-Phe substitution: At position 7, replacing the L-Phe of α-MSH to improve metabolic stability
• Nle substitution: Norleucine replaces Met4 of α-MSH, preventing oxidation

The cyclic lactam constraint enforced by the Asp-Lys bridge is critical for receptor binding geometry. This conformational rigidity enhances the peptide's affinity for MC3R and MC4R while reducing susceptibility to proteolytic degradation — a key consideration for in vitro stability studies.^[3]

MC3R/MC4R Receptor Binding & Selectivity

The melanocortin receptor family comprises five G protein-coupled receptors (GPCRs) that mediate the actions of α-MSH, β-MSH, γ-MSH, and ACTH. PT-141 demonstrates agonist activity at MC3R and MC4R, both of which are expressed predominantly in the central nervous system, with particular density in hypothalamic nuclei.

MC4R: The Primary Research Target

Melanocortin-4 receptor (MC4R) is a Gαs-coupled GPCR expressed at high density in the paraventricular nucleus (PVN), arcuate nucleus, and other hypothalamic regions. Upon PT-141 binding, MC4R activation leads to adenylyl cyclase stimulation, cAMP production, and downstream PKA pathway activation. In vitro studies using Chinese hamster ovary (CHO) cells expressing recombinant human MC4R have characterized PT-141's dose-response curves, EC50 values, and functional coupling efficiency.^[1]

MC4R is notable in the research literature for its role in the leptin-melanocortin pathway, which regulates energy homeostasis and feeding behavior in rodent models. PT-141's agonist activity at this receptor makes it a useful research tool for dissecting MC4R-specific signaling from the broader melanocortin system.

MC3R: CNS and Peripheral Modulation

Melanocortin-3 receptor (MC3R) is expressed in the hypothalamus, limbic system, and peripheral tissues including the gut and immune cells. MC3R functions partly as an autoreceptor on POMC neurons, creating a feedback loop within the melanocortin system. PT-141's affinity for MC3R is of particular interest in studies examining energy balance, neuroinflammation, and POMC neuronal activity. The dual MC3R/MC4R agonism of PT-141 creates a research profile distinct from more selective melanocortin tool compounds.^[2]

Central Nervous System Signaling Pathways

The CNS signaling profile of PT-141 is among the most actively studied aspects of its pharmacology. Melanocortin receptors in the hypothalamus form a critical node in neuroendocrine regulation, and PT-141's ability to penetrate the blood-brain barrier (demonstrated in rodent pharmacokinetic studies) makes it a valuable tool for probing these circuits.

Hypothalamic POMC-AgRP Axis

Within the arcuate nucleus, two opposing neuronal populations regulate melanocortin tone: POMC neurons (which produce α-MSH and activate MC4R) and AgRP neurons (which produce Agouti-Related Peptide, an endogenous MC3R/MC4R antagonist). PT-141, as an exogenous MC4R agonist, mimics the action of α-MSH at the postsynaptic level, activating the same cAMP/PKA cascade that POMC neurons engage. In vitro neuronal cell models and hypothalamic slice preparations have been used to characterize how PT-141 modulates this axis.^[4]

cAMP / PKA Signaling Cascade

PT-141 binding to MC4R (Gαs-coupled) initiates the following intracellular cascade, well-characterized in cell-based assays:

1. Receptor binding → Gαs activation
2. Adenylyl cyclase stimulation → cAMP accumulation
3. PKA activation → CREB phosphorylation
4. Gene expression changes (including neuropeptide and neurotransmitter synthesis regulation)

In CHO-hMC4R cell lines, PT-141 stimulates cAMP production with an EC50 in the low nanomolar range, comparable to α-MSH but with greater resistance to enzymatic degradation — a key advantage for sustained in vitro assay designs.

Dopaminergic and Oxytocinergic Crosstalk

Research in rodent models has identified functional crosstalk between MC4R activation and mesolimbic dopamine signaling. PT-141-induced MC4R activation in the PVN appears to modulate oxytocin release, which in turn interfaces with the ventral tegmental area (VTA) dopaminergic projections. These findings have been explored in preclinical studies using microdialysis and immunohistochemistry, with PT-141 serving as the pharmacological probe.^[5]

Key Research Findings on Melanocortin Receptor Activation

Published in vitro and preclinical research has produced several notable findings regarding PT-141's interaction with the melanocortin system:

Energy Homeostasis Research

Rodent studies using intracerebroventricular (ICV) injection of PT-141 have demonstrated dose-dependent suppression of food intake, consistent with MC4R-mediated hypophagia. These findings are relevant for researchers studying the central melanocortin system's role in metabolic regulation and obesity models. Cell-based studies confirm that PT-141 activates the same signaling pathways downstream of MC4R as endogenous melanocortin peptides, making it a useful pharmacological tool.^[4]

Neuroinflammation Models

MC3R activation has been linked to anti-inflammatory signaling in CNS and peripheral immune models. PT-141's MC3R agonist activity has been investigated in in vitro macrophage and microglial models, where melanocortin receptor activation suppresses pro-inflammatory cytokine production (TNF-α, IL-1β) via cAMP-dependent pathways. These findings position melanocortin agonists including PT-141 as tools for studying neuroinflammatory signaling.

Receptor Internalization & Desensitization

Like most GPCR agonists, chronic MC4R stimulation leads to receptor internalization and desensitization through β-arrestin recruitment and receptor phosphorylation. In vitro studies with fluorescent-tagged MC4R constructs have characterized the kinetics of PT-141-induced receptor internalization, contributing to broader understanding of melanocortin receptor trafficking and tolerance mechanisms.

Comparison with Other Melanocortin Peptides

PT-141's primary advantage over natural α-MSH in research settings is its enhanced in vitro stability. The D-Phe substitution and cyclic lactam bridge dramatically reduce protease susceptibility, allowing for longer assay durations and more consistent concentration maintenance in cell culture media. This stability profile is a key reason PT-141 remains a preferred melanocortin tool compound for CNS-focused research programs.

Compared to the highly selective Setmelanotide, PT-141's dual MC3R/MC4R activity provides a broader pharmacological effect that better mimics endogenous melanocortin tone — useful in studies where the interplay between receptor subtypes is the subject of investigation rather than pure MC4R pathway dissection.

Reconstitution & Storage Guidelines for Researchers

Proper reconstitution and storage of PT-141 lyophilized powder is critical for maintaining peptide integrity and ensuring reproducible experimental results. The following protocols are based on standard peptide handling best practices for research laboratory use.

Step-by-Step Reconstitution Protocol

1. Allow vial to equilibrate to room temperature before opening (prevents condensation contamination)
2. Calculate target volume: For a 1 mg/mL stock of a 10 mg vial, add 10 mL of reconstitution vehicle
3. Add vehicle slowly along the vial wall — do not pipette directly onto the lyophilized cake
4. Gently swirl (do not vortex vigorously) until fully dissolved; solution should be clear and colorless
5. Aliquot immediately into single-use volumes appropriate for your assay design
6. Label with date, concentration, and lot number — maintain chain of custody documentation
7. Store appropriately based on timeline (4°C for <2 weeks; -20°C or -80°C for longer storage)

Stability Considerations

PT-141 is susceptible to oxidation at the Trp residue under prolonged exposure to light or oxygen. Store all solutions in amber vials or wrapped in foil. Working solutions should be prepared fresh from stock aliquots when possible. In cell culture studies, PT-141 stability in complete media (with serum) should be validated for your specific assay duration, as serum proteases — while less active against this cyclic peptide than against linear sequences — can contribute to degradation over extended incubation periods.

For LC-MS/MS quantification of PT-141 in biological matrices, appropriate internal standards and stable isotope-labeled analogues are available from specialty peptide synthesis vendors. Method validation according to FDA Bioanalytical Method Validation Guidance is recommended for any quantitative bioanalytical applications.